Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
Lars Jøran KjerpesethRandi SelmerInger AriansenØystein KarlstadHanne EllekjærEva SkovlundPublished in: PloS one (2019)
After 1 year follow-up in treatment-naïve patients initiating oral anticoagulation for non-valvular atrial fibrillation, all DOACs were similarly effective as warfarin in prevention of ischemic stroke, TIA or systemic embolism. Safety from bleedings was similar or better, including fewer intracranial bleedings with all direct oral anticoagulants, fewer gastrointestinal bleedings with apixaban and fewer other bleedings with dabigatran and apixaban.
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- end stage renal disease
- heart failure
- venous thromboembolism
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- patient reported outcomes
- mitral valve
- aortic valve
- left ventricular
- optic nerve
- drug induced
- patient reported